MX2015005675A - Composiciones y metodos para modular la comunicacion celular. - Google Patents

Composiciones y metodos para modular la comunicacion celular.

Info

Publication number
MX2015005675A
MX2015005675A MX2015005675A MX2015005675A MX2015005675A MX 2015005675 A MX2015005675 A MX 2015005675A MX 2015005675 A MX2015005675 A MX 2015005675A MX 2015005675 A MX2015005675 A MX 2015005675A MX 2015005675 A MX2015005675 A MX 2015005675A
Authority
MX
Mexico
Prior art keywords
compositions
cell signaling
methods
modulating cell
gdas
Prior art date
Application number
MX2015005675A
Other languages
English (en)
Inventor
Timothy Alan Springer
Leonard Ira Zon
Nagesh K Mahanthappa
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of MX2015005675A publication Critical patent/MX2015005675A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente invención suministra agentes dirigidos de factor de crecimiento (GDA), los cuales actúan bien sea como antagonistas o agonistas de señalización celular, particularmente en el TGE-beta y las trayectorias de señalización de matriz extracelular relacionadas. Dichos GDA incluyen anticuerpos monoclonales, proteínas de fusión y composiciones de polipéptido novedosas y/o conjugados de estas composiciones.
MX2015005675A 2012-11-06 2013-11-06 Composiciones y metodos para modular la comunicacion celular. MX2015005675A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722969P 2012-11-06 2012-11-06
US201261722919P 2012-11-06 2012-11-06
PCT/US2013/068613 WO2014074532A2 (en) 2012-11-06 2013-11-06 Compositions and methods for modulating cell signaling

Publications (1)

Publication Number Publication Date
MX2015005675A true MX2015005675A (es) 2016-02-03

Family

ID=50685303

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005675A MX2015005675A (es) 2012-11-06 2013-11-06 Composiciones y metodos para modular la comunicacion celular.

Country Status (10)

Country Link
US (2) US20150284455A1 (es)
EP (1) EP2916867A4 (es)
JP (3) JP2016500704A (es)
AU (3) AU2013341353B2 (es)
CA (2) CA3023553A1 (es)
IL (1) IL238488B (es)
MX (1) MX2015005675A (es)
SG (2) SG10201704616SA (es)
WO (1) WO2014074532A2 (es)
ZA (1) ZA201502884B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
KR102469853B1 (ko) 2008-04-11 2022-11-22 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
US9944700B2 (en) 2013-03-13 2018-04-17 Novartis Ag Notch2 binding molecules for treating respiratory diseases
US11267868B2 (en) 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
SG10201913751RA (en) 2013-05-06 2020-03-30 Scholar Rock Inc Compositions and methods for growth factor modulation
CA3005158A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EP4183806A3 (en) 2014-11-12 2023-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
PE20221834A1 (es) * 2014-12-19 2022-11-29 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina
CA2973978A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
KR20170110129A (ko) 2015-02-05 2017-10-10 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
EP3324996A4 (en) * 2015-07-22 2019-04-17 Scholar Rock, Inc. GDF11 BINDING PROTEINS AND USES THEREOF
LT3350220T (lt) 2015-09-15 2021-09-27 Scholar Rock, Inc. Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
IL288784B2 (en) * 2015-09-24 2023-10-01 Daiichi Sankyo Co Ltd Antibodies against GARP, nucleotides encoding them, and vectors, cells and preparations containing them, methods for their preparation and uses thereof
IL258768B2 (en) 2015-11-12 2023-11-01 Siamab Therapeutics Inc Compounds interacting with glycans and methods of use
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN109071645A (zh) 2016-01-08 2018-12-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
EP3411475A4 (en) 2016-02-06 2019-09-11 President and Fellows of Harvard College REGENERATION OF THE HEMATOPOIETIC NICHE TO RECONSTITUTE IMMUNITY
PL3365368T3 (pl) 2016-03-11 2023-08-21 Scholar Rock, Inc. Immunoglobuliny wiążące tgfbeta1 i ich zastosowanie
JP6869324B2 (ja) * 2016-03-31 2021-05-12 チャンスー ヤホン メディテック カンパニー リミテッド ニトロキソリンおよびその類似体と、化学療法剤および免疫療法剤との、がんの治療における、組合せの使用
KR102271635B1 (ko) 2016-06-13 2021-07-06 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
AU2017325973A1 (en) * 2016-09-15 2019-03-07 Acceleron Pharma Inc. Twisted gastrulation polypeptides and uses thereof
FI3565592T3 (fi) 2017-01-06 2023-05-10 Scholar Rock Inc Metabolisten tautien hoitaminen estämällä myostatiinin aktivaatio
AU2018255244A1 (en) 2017-04-21 2019-10-31 Mellitus, Llc Methods and antibodies for diabetes-related applications
PL3621694T3 (pl) 2017-05-09 2024-02-05 Scholar Rock, Inc. Inhibitory lrrc33 i ich zastosowanie
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
EP3749365A4 (en) 2018-01-29 2022-01-12 Ohio State Innovation Foundation PEPTIDY INHIBITORS OF THE CALCINEURIN-NFAT INTERACTION
PL3677278T3 (pl) 2018-07-11 2022-02-28 Scholar Rock, Inc. Selektywne względem izoformy inhibitory tgfbeta1 i ich zastosowanie
JP2022504839A (ja) 2018-10-10 2022-01-13 ティロス・セラピューティクス・インコーポレイテッド 抗ｌａｐ抗体変異体及びその使用
JP2022524281A (ja) 2019-01-30 2022-05-02 スカラー ロック インコーポレイテッド ＴＧＦβのＬＴＢＰ複合体特異的阻害剤およびその使用
EP3966227A1 (en) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
WO2021030303A1 (en) 2019-08-12 2021-02-18 Voyager Therapeutics, Inc. High-sensitivity immunoassay for the detection of frataxin in biofluids
PE20221447A1 (es) 2019-08-28 2022-09-21 Chugai Pharmaceutical Co Ltd Anticuerpos anti-tgf-beta 1 latente y metodos de uso
CN111474336B (zh) * 2020-03-21 2023-07-28 南昌大学 一种铁氰化镍纳米粒化学发光适体传感器的制备方法及基于其检测8-OhdG的方法
WO2022099093A1 (en) * 2020-11-06 2022-05-12 President And Fellows Of Harvard College Scaffolds for enhancing neutrophils and uses thereof
AU2021400488A1 (en) 2020-12-14 2023-06-22 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
CN113061575B (zh) * 2021-03-25 2023-04-07 中国人民解放军陆军军医大学 从大龄小鼠结肠固有层中分离纯化固有淋巴样细胞的方法
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
CN115286701A (zh) * 2022-03-07 2022-11-04 江苏靶标生物医药研究所有限公司 一种调节哺乳动物的肠道粘膜稳态或炎症性肠病的靶点及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262319A (en) * 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
JP3452946B2 (ja) * 1992-02-19 2003-10-06 協和醗酵工業株式会社 抗ＴＧＦ−βマスキングプロテインモノクローナル抗体
AU5587094A (en) * 1992-10-26 1994-05-24 Kirin Brewery Company, Limited Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
EP0754058B1 (en) * 1994-03-29 1999-11-03 The Victoria University Of Manchester Wound healing
US5616561A (en) * 1995-03-31 1997-04-01 Regents Of The University Of California TGF-β antagonists as mitigators of radiation-induced tissue damage
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
WO2005013915A2 (en) * 2003-08-08 2005-02-17 The Regents Of The University Of California Novel indications for transforming growth factor-beta regulators
WO2006106599A1 (ja) * 2005-03-01 2006-10-12 Kyoto University 細胞外ドメインシェディングの異常亢進に起因する疾患の予防及び／又は治療のための医薬
EP1948675B1 (en) * 2005-10-25 2014-07-30 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
US8236527B2 (en) * 2008-03-14 2012-08-07 Humanzyme Limited Recombinant production of authentic human proteins using human cell expression systems
GB0809592D0 (en) * 2008-05-27 2008-07-02 Imp Innovations Ltd Biomaterials

Also Published As

Publication number Publication date
EP2916867A4 (en) 2016-10-05
AU2017203805B2 (en) 2019-08-15
JP2017132796A (ja) 2017-08-03
SG11201503271XA (en) 2015-05-28
WO2014074532A3 (en) 2014-06-26
US20150284455A1 (en) 2015-10-08
CA3023553A1 (en) 2014-05-15
AU2019264599A1 (en) 2019-12-05
AU2017203805A1 (en) 2017-06-22
JP2016500704A (ja) 2016-01-14
JP2019163317A (ja) 2019-09-26
EP2916867A2 (en) 2015-09-16
AU2013341353B2 (en) 2017-03-16
SG10201704616SA (en) 2017-07-28
CA2890733A1 (en) 2014-05-15
IL238488A0 (en) 2015-06-30
US20200024339A1 (en) 2020-01-23
WO2014074532A2 (en) 2014-05-15
ZA201502884B (en) 2016-01-27
IL238488B (en) 2020-04-30
AU2013341353A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
MX2015005675A (es) Composiciones y metodos para modular la comunicacion celular.
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2022000132A (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
MX2021006400A (es) Celulas t de memoria central para terapia adoptiva de celulas t.
EA201170030A1 (ru) Il-6-опосредованная иммунотерапия
EA201890423A1 (ru) Слитые белки фактора ix, способы их получения и применения
AU2013211824A8 (en) Fusion proteins comprising IgG2 hinge domains
MX2014014951A (es) Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
MX2017006866A (es) Pares de unión para producción de péptidos.
MX2016012713A (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
WO2013115926A3 (en) Aspartyl-trna synthetase-fc conjugates
MX347515B (es) Agentes que se unen al receptor encrespado y usos de los mismos.
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
MX366178B (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
MX2017000083A (es) Compuestos de platino, composiciones y usos de estos.
PH12014501970A1 (en) Antibodies to bradykinin b1 receptor ligands
EA201491107A1 (ru) Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
MX2015005231A (es) Composicion farmaceutica estable de la proteina de fusion tnfr:fc.
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
NZ703546A (en) Composition comprising a mixture of cd95-fc isoforms
NZ713602A (en) Method for refining protein including self-cutting cassette and use thereof
MX2015014568A (es) Composiciones y metodos para tratar y prevenir la degeneracion macular.
MX2015015051A (es) Formulaciones alternativas para polipeptidos de fusion tnfr:fc.